S100A11: A Potential Drug Target for T Cell Development and Function

Target Name: S100A11

NCBI ID: G6282

S100A11

S100A11: A Potential Drug Target for T Cell Development and Function

S100A11 (also known as metastatic lymph node gene 70 protein) is a protein that is expressed in various tissues throughout the body, including the lymph nodes. It is a member of the S100 family of proteins, which are known for their role in cell signaling and communication. S100A11 has been shown to play a role in the regulation of T cell development and function, and has potential as a drug target or biomarker.

S100A11 is a 21-kDa protein that is expressed in a variety of tissues, including the lymph nodes, spleen, tonsils, and bone marrow. It is a member of the S100 family of proteins, which are characterized by the presence of a characteristic domain called the N-terminal transmembrane segment (TMS) and a unique C-terminal region that is involved in protein-protein interactions. The TMS region is thought to play a role in the stability and localization of the protein, while the C-terminal region is involved in its interactions with other proteins.

S100A11 has been shown to be involved in the regulation of T cell development and function. T cells are a type of immune cell that play a critical role in protecting the body against infection and disease. They are generated from hematopoietic stem cells and differentiate into T cells, which are responsible for cell-mediated immunity. S100A11 has been shown to be involved in the regulation of T cell development by promoting the growth and differentiation of T cells, as well as regulating their survival and proliferation.

S100A11 has also been shown to play a role in the regulation of T cell receptor (TCR) function. TCR is a protein that is found on the surface of T cells, and is responsible for recognizing and responding to foreign antigens. S100A11 has been shown to be involved in the regulation of TCR function by interacting with the protein co-regulator FTCN1. This interaction between S100A11 and FTCN1 allows for the regulation of TCR function and the development of T cell responses to antigens.

In addition to its role in T cell development and function, S100A11 has also been shown to be involved in the regulation of inflammation. Chronic inflammation can lead to a host of diseases, including cancer, autoimmune diseases, and chronic obstructive pulmonary disease (COPD). S100A11 has been shown to be involved in the regulation of inflammation by promoting the production of pro-inflammatory cytokines and contributing to the recruitment of immune cells to sites of inflammation.

S100A11 has also been shown to have potential as a drug target or biomarker. Its involvement in T cell development and function, as well as its role in the regulation of inflammation, make it a promising target for the development of new therapeutic approaches. S100A11 has been shown to interact with a variety of proteins, including the transcription factor PDGF-1, the chemokine IL-12, and the protein PD-L1. These interactions suggest that S100A11 may be a useful target for the development of drugs that can modulate T cell function and prevent the development of autoimmune diseases.

In conclusion, S100A11 is a protein that has been shown to play a role in the regulation of T cell development and function, as well as the regulation of inflammation. Its potential as a drug target or biomarker makes it an attractive target for the development of new therapeutic approaches. Further research is needed to fully understand the role of S100A11 in T cell development and function, as well as its potential as a drug target or biomarker.

Protein Name: S100 Calcium Binding Protein A11

Functions: Facilitates the differentiation and the cornification of keratinocytes

The "S100A11 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about S100A11 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets